Interstitial Lung Disease clinical trials at UCSD
2 in progress, 1 open to eligible people
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
open to eligible people ages 18-75
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
La Jolla, California and other locations
Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Sorry, accepting new patients by invitation only
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
La Jolla, California and other locations
Last updated: